JP2016509583A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509583A5 JP2016509583A5 JP2015549787A JP2015549787A JP2016509583A5 JP 2016509583 A5 JP2016509583 A5 JP 2016509583A5 JP 2015549787 A JP2015549787 A JP 2015549787A JP 2015549787 A JP2015549787 A JP 2015549787A JP 2016509583 A5 JP2016509583 A5 JP 2016509583A5
- Authority
- JP
- Japan
- Prior art keywords
- nhr
- alkyl
- nhc
- tautomer
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 78
- -1 2-cyclopropylethynyl Chemical group 0.000 claims 50
- 239000012453 solvate Substances 0.000 claims 30
- 150000003839 salts Chemical class 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 26
- 229910052757 nitrogen Inorganic materials 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 150000002367 halogens Chemical class 0.000 claims 17
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000000470 constituent Substances 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 102000001253 Protein Kinase Human genes 0.000 claims 4
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 4
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 108060006633 protein kinase Proteins 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 229910052796 boron Inorganic materials 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 claims 2
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000586 2-(4-morpholinyl)ethoxy group Chemical group [H]C([H])(O*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000001845 4 membered carbocyclic group Chemical group 0.000 claims 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 101100240519 Caenorhabditis elegans nhr-13 gene Proteins 0.000 claims 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- ICPMUWPXCAVOOQ-UHFFFAOYSA-N cycloocta-1,3,5-triene Chemical compound C1CC=CC=CC=C1 ICPMUWPXCAVOOQ-UHFFFAOYSA-N 0.000 claims 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 claims 1
- 239000004914 cyclooctane Substances 0.000 claims 1
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000004130 indan-2-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])(*)C2([H])[H] 0.000 claims 1
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 0 *c1ccccc1 Chemical compound *c1ccccc1 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745409P | 2012-12-21 | 2012-12-21 | |
| US61/745,409 | 2012-12-21 | ||
| US201361784928P | 2013-03-14 | 2013-03-14 | |
| US61/784,928 | 2013-03-14 | ||
| PCT/US2013/076995 WO2014100620A2 (en) | 2012-12-21 | 2013-12-20 | Compounds and methods for kinase modulation, and indications therefor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018019358A Division JP2018109013A (ja) | 2012-12-21 | 2018-02-06 | キナーゼ調節のための化合物および方法、ならびにその適応 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016509583A JP2016509583A (ja) | 2016-03-31 |
| JP2016509583A5 true JP2016509583A5 (enExample) | 2017-02-09 |
| JP6385954B2 JP6385954B2 (ja) | 2018-09-05 |
Family
ID=50001255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549787A Active JP6385954B2 (ja) | 2012-12-21 | 2013-12-20 | キナーゼ調節のための化合物および方法、ならびにその適応 |
| JP2018019358A Withdrawn JP2018109013A (ja) | 2012-12-21 | 2018-02-06 | キナーゼ調節のための化合物および方法、ならびにその適応 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018019358A Withdrawn JP2018109013A (ja) | 2012-12-21 | 2018-02-06 | キナーゼ調節のための化合物および方法、ならびにその適応 |
Country Status (33)
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006332726B2 (en) | 2005-12-28 | 2012-12-13 | Vertex Pharmaceuticals Incorporated. | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| KR20120097512A (ko) | 2009-11-18 | 2012-09-04 | 플렉시콘, 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| KR20120112623A (ko) | 2009-12-23 | 2012-10-11 | 플렉시콘, 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| WO2012109075A1 (en) | 2011-02-07 | 2012-08-16 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| RU2631487C2 (ru) | 2011-05-17 | 2017-09-22 | Плексксикон Инк. | Модуляция киназ и показания к её применению |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| JP6318156B2 (ja) | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| PE20151280A1 (es) | 2012-12-21 | 2015-09-12 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas y sus indicaciones |
| ES2865402T3 (es) | 2012-12-21 | 2021-10-15 | Janssen Biopharma Inc | 4'-fluoronucleósidos, 4'-fluoronucleótidos y análogos de los mismos para el tratamiento del VHC |
| TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調節劑 |
| ES2666155T3 (es) | 2013-03-14 | 2018-05-03 | Janssen Pharmaceutica Nv | Moduladores de P2X7 |
| WO2014140075A1 (en) | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| JO3509B1 (ar) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | معدلات p2x7 |
| WO2014152537A1 (en) | 2013-03-14 | 2014-09-25 | Janssen Pharmaceutica Nv | P2x7 modulators |
| NZ630875A (en) | 2013-03-15 | 2017-12-22 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| CA2912568A1 (en) | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| RS57542B1 (sr) | 2013-10-17 | 2018-10-31 | Blueprint Medicines Corp | Kompozicije korisne za lečenje poremećaja povezanih sa kit-om |
| WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| SG11201607895PA (en) | 2014-05-28 | 2016-12-29 | Novartis Ag | Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors |
| EP3157915B1 (en) | 2014-06-17 | 2019-02-27 | Pfizer Inc | Substituted dihydroisoquinolinone compounds |
| CN108047240B (zh) | 2014-09-12 | 2020-08-04 | 勃林格殷格翰国际有限公司 | 组织蛋白酶c的螺环化合物抑制剂 |
| CA2960968A1 (en) | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulators |
| AU2015315693B2 (en) | 2014-09-12 | 2020-01-16 | Janssen Pharmaceutica Nv | P2X7 modulating n-acyl-triazolopyrazines |
| WO2016044067A1 (en) | 2014-09-15 | 2016-03-24 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| CA2972239A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MX386963B (es) | 2015-05-06 | 2025-03-19 | Daiichi Sankyo Inc | Formas sólidas de quinasas que modulan un compuesto. |
| ES2923943T3 (es) | 2015-05-06 | 2022-10-03 | Plexxikon Inc | Síntesis de un compuesto que modula cinasas |
| CA2986735A1 (en) | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
| CN110078730B (zh) * | 2015-07-11 | 2021-09-07 | 南京爱德程医药科技有限公司 | 作为pi3k/mtor抑制剂的喹啉取代的稠合喹啉化合物 |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CA3129180A1 (en) | 2015-09-21 | 2017-03-30 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| WO2017064217A1 (en) * | 2015-10-13 | 2017-04-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis |
| US9938273B2 (en) | 2015-12-07 | 2018-04-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP6921846B6 (ja) | 2016-03-16 | 2021-09-15 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼ調節およびその適応症のための化合物および方法 |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| JP7193460B2 (ja) | 2016-12-23 | 2022-12-20 | プレキシコン インコーポレーテッド | Ｃｄｋ８調節およびその適応症のための化合物および方法 |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| WO2018175311A1 (en) | 2017-03-20 | 2018-09-27 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
| WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
| KR102615829B1 (ko) | 2017-07-25 | 2023-12-20 | 플렉시콘 인코퍼레이티드 | 키나제를 조정하는 화합물의 제제 |
| AU2018348241B2 (en) | 2017-10-13 | 2023-01-12 | Opna Bio SA | Solid forms of a compound for modulating kinases |
| CA3080197C (en) | 2017-10-27 | 2023-12-19 | Plexxikon Inc. | Formulations of a compound modulating kinases |
| EP3768666A1 (en) | 2018-03-20 | 2021-01-27 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
| WO2019201194A1 (zh) * | 2018-04-16 | 2019-10-24 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡咯并三嗪类化合物及其药物组合物及其用途 |
| JP7590185B2 (ja) | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| WO2020021024A1 (en) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
| WO2020065613A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| MA53722A (fr) | 2018-09-28 | 2022-03-30 | Janssen Pharmaceutica Nv | Modulateurs de la monoacylglycérol lipase |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| MX2021010122A (es) | 2019-02-22 | 2021-09-23 | 1St Biotherapeutics Inc | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. |
| SG11202110714VA (en) | 2019-04-09 | 2021-10-28 | Plexxikon Inc | Condensed azines for ep300 or cbp modulation and indications therefor |
| MA55604B1 (fr) | 2019-04-12 | 2024-08-30 | Blueprint Medicines Corporation | Dérivés de pyrrolotriazine pour le traitement de maladies liées au kit- and pdgfra |
| CN113966334B (zh) | 2019-04-12 | 2025-01-21 | 缆图药品公司 | 化合物(i)的晶体形式 |
| TW202115077A (zh) * | 2019-07-01 | 2021-04-16 | 大陸商上海齊魯銳格醫藥研發有限公司 | Ｍａｌｔ１抑制劑及其用途 |
| EP4038070B1 (en) | 2019-09-30 | 2025-07-09 | Janssen Pharmaceutica NV | Radiolabelled mgl pet ligands |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| MX2022008875A (es) | 2020-01-20 | 2022-08-11 | Genzyme Corp | Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr). |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| EP4126860A1 (en) | 2020-03-26 | 2023-02-08 | Janssen Pharmaceutica NV | Monoacylglycerol lipase modulators |
| CA3176237A1 (en) | 2020-04-29 | 2021-11-04 | Jack Lin | Synthesis of heterocyclic compounds |
| KR20220034504A (ko) | 2020-09-11 | 2022-03-18 | 아주대학교산학협력단 | 셀루메티닙을 유효성분으로 포함하는 퇴행성 관절염 예방 또는 치료용 조성물 |
| CN112159423A (zh) * | 2020-11-03 | 2021-01-01 | 凯美克(上海)医药科技有限公司 | 1H-吡咯并[2,3-b]吡啶-2-硼酸频哪醇酯的合成方法 |
| MX2023006854A (es) | 2020-12-10 | 2023-07-20 | Genzyme Corp | Forma cristalina de tolebrutinib, metodo de preparacion y uso de la misma. |
| EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US20230192686A1 (en) * | 2021-10-12 | 2023-06-22 | Biosplice Therapeutics, Inc. | 1h-pyrrolo[2,3-b]pyridines and preparation and uses thereof |
| IL312157A (en) | 2021-10-12 | 2024-06-01 | Biosplice Therapeutics Inc | History of pyrrolo[1,2-F][4,2,1]triazines as DYRK1A inhibitors |
| CA3234909A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP2024541979A (ja) | 2021-10-29 | 2024-11-13 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| KR20240125012A (ko) | 2021-12-22 | 2024-08-19 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| DK4245756T3 (da) | 2022-03-17 | 2024-10-21 | Gilead Sciences Inc | Ikaros zinkfinger-familiens nedbrydere og anvendelse heraf |
| IL316058A (en) | 2022-04-21 | 2024-11-01 | Gilead Sciences Inc | Compounds modulate KRAS G12D |
| CR20240570A (es) | 2022-07-01 | 2025-03-03 | Gilead Sciences Inc | Compuestos de cd73 |
| CN115227692A (zh) * | 2022-09-05 | 2022-10-25 | 中国医学科学院基础医学研究所 | Reblastatin在制备治疗慢性惊厥的药物中的用途 |
| KR20250122479A (ko) | 2022-12-22 | 2025-08-13 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| CN120676932A (zh) * | 2022-12-22 | 2025-09-19 | 科根生物科学股份有限公司 | 贝祖拉替尼制剂 |
| US20240383922A1 (en) | 2023-04-11 | 2024-11-21 | Gilead Sciences, Inc. | KRAS Modulating Compounds |
| AU2024259556A1 (en) | 2023-04-21 | 2025-10-23 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250100998A1 (en) | 2023-07-26 | 2025-03-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025026050A1 (zh) * | 2023-07-28 | 2025-02-06 | 苏州科睿思制药有限公司 | Bezuclastinib的晶型及其制备方法和用途 |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7078391B2 (en) | 1997-02-10 | 2006-07-18 | Inspire Pharmaceuticals, Inc. | Method of treating edematous retinal disorders |
| GB9824310D0 (en) * | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| MXPA02006263A (es) | 1999-12-22 | 2004-02-26 | Sugen Inc | Metodos de modulacion de la funcion de la cinasa de tirosina c-kit de la proteina con compuestos de indolinona. |
| EP1326831A1 (en) * | 2000-09-06 | 2003-07-16 | Neurogen Corporation | Substituted fused pyrroleimines and pyrazoleimines |
| US20040171062A1 (en) | 2002-02-28 | 2004-09-02 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
| EP1495016A2 (en) | 2002-04-09 | 2005-01-12 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
| GB0218625D0 (en) * | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| JP2006502301A (ja) | 2002-09-06 | 2006-01-19 | インサート セラピューティクス インコーポレイテッド | 治療剤配送のためのシクロデキストリン基材重合体 |
| AU2003272548A1 (en) | 2002-09-16 | 2004-04-30 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
| FR2845382A1 (fr) * | 2002-10-02 | 2004-04-09 | Sanofi Synthelabo | Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique |
| US20050048573A1 (en) | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
| EP1627045A2 (en) | 2003-02-28 | 2006-02-22 | Plexxikon, Inc. | Pyk2 crystal structure and uses |
| WO2004108133A2 (en) | 2003-06-05 | 2004-12-16 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
| US20050079548A1 (en) | 2003-07-07 | 2005-04-14 | Plexxikon, Inc. | Ligand development using PDE4B crystal structures |
| CA2532403A1 (en) | 2003-07-17 | 2005-02-03 | James Arnold | Ppar active compounds |
| US7348338B2 (en) | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
| EP1658289B1 (en) * | 2003-08-21 | 2009-03-18 | OSI Pharmaceuticals, Inc. | 3-substituted imidazopyridine-derivatives as c-kit inhibitors |
| US7442709B2 (en) * | 2003-08-21 | 2008-10-28 | Osi Pharmaceuticals, Inc. | N3-substituted imidazopyridine c-Kit inhibitors |
| WO2005028624A2 (en) | 2003-09-15 | 2005-03-31 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
| US20070066641A1 (en) | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
| US7517970B2 (en) | 2003-12-19 | 2009-04-14 | Plexxikon, Inc. | Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same |
| CN1925855B (zh) | 2003-12-19 | 2010-06-16 | 普莱希科公司 | 开发Ret调节剂的化合物和方法 |
| GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
| US7452730B2 (en) | 2004-01-16 | 2008-11-18 | California Institute Of Technology | DNA-binding polymers |
| WO2005094805A1 (ja) | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
| CA2565965A1 (en) | 2004-05-06 | 2006-07-27 | Plexxikon, Inc. | Pde4b inhibitors and uses therefor |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| US20060058339A1 (en) | 2004-06-17 | 2006-03-16 | Ibrahim Prabha N | Compounds modulating c-kit activity and uses therefor |
| US7605168B2 (en) | 2004-09-03 | 2009-10-20 | Plexxikon, Inc. | PDE4B inhibitors |
| JP2008513426A (ja) * | 2004-09-20 | 2008-05-01 | バイオリポックス エービー | 炎症の治療に有用なピラゾール化合物 |
| US20060135540A1 (en) | 2004-11-30 | 2006-06-22 | Jack Lin | PPAR active compounds |
| WO2006060456A2 (en) | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Indole derivatives for use as ppar ppar active compounds |
| US20060160135A1 (en) | 2004-12-08 | 2006-07-20 | Weiru Wang | SF-1 and LRH-1 modulator development |
| JP2008528469A (ja) * | 2005-01-21 | 2008-07-31 | アステックス・セラピューティクス・リミテッド | ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤 |
| MX2007014377A (es) | 2005-05-17 | 2008-02-06 | Plexxikon Inc | Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina. |
| UA93679C2 (en) * | 2005-05-17 | 2011-03-10 | Плексикон, Инк. | Compounds modulating c-kit and c-fms activity and uses therefor |
| DK2395004T3 (en) | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| US20100234379A1 (en) | 2005-07-28 | 2010-09-16 | Bahr Ben A | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity |
| US7754717B2 (en) * | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| AU2006287521A1 (en) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | PPARactive compounds |
| WO2007030574A2 (en) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds |
| CN101304992A (zh) | 2005-09-07 | 2008-11-12 | 普莱希科公司 | 用作ppar调节剂的1,3-二取代吲哚衍生物 |
| TW200732320A (en) | 2005-10-31 | 2007-09-01 | Biolipox Ab | Pyrazoles useful in the treatment of inflammation |
| AR063311A1 (es) | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| NZ577798A (en) * | 2006-12-21 | 2012-04-27 | Vertex Pharma | 5-cyano-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| US7872018B2 (en) | 2006-12-21 | 2011-01-18 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
| AU2008222807A1 (en) | 2007-03-08 | 2008-09-12 | Plexxikon, Inc. | PPAR active compounds |
| PE20090159A1 (es) | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
| WO2008112695A2 (en) * | 2007-03-12 | 2008-09-18 | Irm Llc | Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment |
| WO2008144253A1 (en) * | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
| US20090076275A1 (en) | 2007-09-19 | 2009-03-19 | David Robert Bolin | Diacylglycerol acyltransferase inhibitors |
| WO2009073788A1 (en) | 2007-12-07 | 2009-06-11 | Firestone Leigh H | Compositions and methods for treating menopausal females |
| WO2009112445A1 (en) | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
| WO2009152083A1 (en) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | 5h-pyrr0l0 [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor |
| US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
| FR2941948B1 (fr) * | 2009-02-12 | 2013-04-05 | Nova Decision | Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src |
| KR101663339B1 (ko) | 2009-03-11 | 2016-10-06 | 플렉시콘 인코퍼레이티드 | Ｒａｆ 키나제의 억제를 위한 피롤로［２,３-ｂ］피리딘 유도체 |
| KR20110130463A (ko) | 2009-03-11 | 2011-12-05 | 플렉시콘, 인코퍼레이티드 | Ｒａｆ 키나제의 억제를 위한 피롤로［２,３-ｂ］피리딘 유도체 |
| WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
| KR20170058465A (ko) | 2009-04-03 | 2017-05-26 | 에프. 호프만-라 로슈 아게 | 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도 |
| SG175877A1 (en) | 2009-05-04 | 2011-12-29 | Plexxikon Inc | Compounds and methods for inhibition of renin, and indications therefor |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2011024869A1 (ja) | 2009-08-26 | 2011-03-03 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
| AU2010315126B2 (en) | 2009-11-06 | 2015-06-25 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| KR20120097512A (ko) | 2009-11-18 | 2012-09-04 | 플렉시콘, 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| KR20120112623A (ko) | 2009-12-23 | 2012-10-11 | 플렉시콘, 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| LT2522658T (lt) * | 2010-01-04 | 2018-11-26 | Nippon Soda Co., Ltd. | Heterociklinis junginys, kurio sudėtyje yra azotas, ir žemės ūkio/sodininkystės germicidas |
| WO2011116176A1 (en) | 2010-03-17 | 2011-09-22 | Sirtris Pharmaceuticals Inc. | 3-substitued imidazo (4, 5-b) pyridines and analogs as sirtuin modulators |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| US8642606B2 (en) | 2010-09-29 | 2014-02-04 | Plexxikon Inc. | ZAP-70 active compounds |
| WO2012109075A1 (en) | 2011-02-07 | 2012-08-16 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| RU2631487C2 (ru) | 2011-05-17 | 2017-09-22 | Плексксикон Инк. | Модуляция киназ и показания к её применению |
| HRP20190281T1 (hr) * | 2011-09-14 | 2019-05-31 | Samumed, Llc | Indazol-3-karboksamidi i njihova uporaba kao inhibitora signalizacijskog puta wnt/b-katenin |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| JP6318156B2 (ja) | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
| PE20151280A1 (es) | 2012-12-21 | 2015-09-12 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas y sus indicaciones |
| NZ630875A (en) | 2013-03-15 | 2017-12-22 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| UY35400A (es) * | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| CA2912568A1 (en) | 2013-05-30 | 2014-12-04 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2016044067A1 (en) | 2014-09-15 | 2016-03-24 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| ES2923943T3 (es) | 2015-05-06 | 2022-10-03 | Plexxikon Inc | Síntesis de un compuesto que modula cinasas |
| MX386963B (es) | 2015-05-06 | 2025-03-19 | Daiichi Sankyo Inc | Formas sólidas de quinasas que modulan un compuesto. |
| CA2986735A1 (en) | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
| US9814714B2 (en) | 2015-05-22 | 2017-11-14 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CA3129180A1 (en) | 2015-09-21 | 2017-03-30 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| US9938273B2 (en) | 2015-12-07 | 2018-04-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP6921846B6 (ja) | 2016-03-16 | 2021-09-15 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼ調節およびその適応症のための化合物および方法 |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
-
2013
- 2013-12-20 PE PE2015001026A patent/PE20151280A1/es active IP Right Grant
- 2013-12-20 AR ARP130105005A patent/AR094263A1/es unknown
- 2013-12-20 NZ NZ711896A patent/NZ711896A/en active IP Right Revival
- 2013-12-20 BR BR112015014752-6A patent/BR112015014752B1/pt active IP Right Grant
- 2013-12-20 WO PCT/US2013/076995 patent/WO2014100620A2/en not_active Ceased
- 2013-12-20 SI SI201330984T patent/SI2935248T1/en unknown
- 2013-12-20 TW TW102147664A patent/TWI617552B/zh active
- 2013-12-20 DK DK13824239.1T patent/DK2935248T3/en active
- 2013-12-20 ES ES13824239.1T patent/ES2664985T3/es active Active
- 2013-12-20 PT PT138242391T patent/PT2935248T/pt unknown
- 2013-12-20 CN CN201380072669.5A patent/CN105308036B/zh active Active
- 2013-12-20 MX MX2015008043A patent/MX365640B/es active IP Right Grant
- 2013-12-20 SG SG10201707095QA patent/SG10201707095QA/en unknown
- 2013-12-20 UY UY0001035240A patent/UY35240A/es not_active Application Discontinuation
- 2013-12-20 CA CA2895239A patent/CA2895239C/en active Active
- 2013-12-20 JP JP2015549787A patent/JP6385954B2/ja active Active
- 2013-12-20 HR HRP20180499TT patent/HRP20180499T1/hr unknown
- 2013-12-20 EP EP13824239.1A patent/EP2935248B1/en active Active
- 2013-12-20 KR KR1020157019388A patent/KR102212923B1/ko active Active
- 2013-12-20 AU AU2013361127A patent/AU2013361127B2/en active Active
- 2013-12-20 US US14/137,438 patent/US9676748B2/en active Active
- 2013-12-20 SM SM20180230T patent/SMT201800230T1/it unknown
- 2013-12-20 SG SG11201504754QA patent/SG11201504754QA/en unknown
- 2013-12-20 ME MEP-2018-84A patent/ME03000B/me unknown
- 2013-12-20 PL PL13824239T patent/PL2935248T3/pl unknown
- 2013-12-20 RU RU2015126485A patent/RU2666146C2/ru not_active Application Discontinuation
- 2013-12-20 RS RS20180396A patent/RS57117B1/sr unknown
- 2013-12-20 LT LTEP13824239.1T patent/LT2935248T/lt unknown
- 2013-12-20 HU HUE13824239A patent/HUE036739T2/hu unknown
-
2015
- 2015-06-16 IL IL239458A patent/IL239458B/en active IP Right Grant
- 2015-06-17 PH PH12015501370A patent/PH12015501370A1/en unknown
- 2015-06-19 CL CL2015001785A patent/CL2015001785A1/es unknown
- 2015-07-07 ZA ZA2015/04872A patent/ZA201504872B/en unknown
-
2017
- 2017-06-12 US US15/620,396 patent/US10301280B2/en active Active
-
2018
- 2018-02-06 JP JP2018019358A patent/JP2018109013A/ja not_active Withdrawn
- 2018-05-25 CY CY20181100565T patent/CY1120421T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016509583A5 (enExample) | ||
| RU2015126485A (ru) | Соединения и способы модулирования киназы и показания к их применению | |
| JP2015529224A5 (enExample) | ||
| JP2019512505A5 (enExample) | ||
| JP2019529484A5 (enExample) | ||
| JP7592689B2 (ja) | Ｓｔｉｎｇアゴニストとしての大環状化合物並びにその方法及び使用 | |
| JP2016523973A5 (enExample) | ||
| JP2017526726A5 (enExample) | ||
| JP2017528498A5 (enExample) | ||
| JP2018507877A5 (enExample) | ||
| JP2018520195A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2019031560A5 (enExample) | ||
| JP2018515438A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2013509431A5 (enExample) | ||
| RU2011137399A (ru) | Гетероциклическое производное | |
| TW202120500A (zh) | 干擾素基因刺激蛋白（ｓｔｉｎｇ）激動劑化合物及用途 | |
| JP2014503567A5 (enExample) | ||
| JP2016517417A5 (enExample) | ||
| JP2016514719A5 (enExample) | ||
| JP2014505735A5 (enExample) | ||
| JP2016523974A5 (enExample) | ||
| JP2010539110A5 (enExample) | ||
| JP2017505808A5 (enExample) |